



RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021



Endo International plc Rank 18 of 409



The relative strengths and weaknesses of Endo International plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endo International plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 261% points. The greatest weakness of Endo International plc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 537% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,413,258
Cost of Goods Sold	1,442,511
Intangible Assets	6,300,819
Liabilities, Current	1,253,824
Liabilities, Non-Current	0
Other Assets	550,560
Other Compr. Net Income	1,337
Other Expenses	395,850
Other Liabilities	0
Other Net Income	-23,361
Property and Equipment	0
Research and Development	158,902
Revenues	2,903,074
Selling, General and Administrative Expense	698,506

Output Variable	Value in 1000 USD
Assets	9,264,637
Liabilities	1,253,824
Expenses	2,695,769
Stockholders Equity	8,010,813
Net Income	183,944
Comprehensive Net Income	184,612
Economic Capital Ratio	182%

